Is the price fair?
What GSK's price assumes
GSK plc has no trailing P/E on file, so the price is measured against sales instead: 1.58× revenue.
1.58
Price / sales · no trailing P/E on file: measured against sales instead
- Price / book
- 11.9
Price / book · as of 2025-FY
- EV / sales
- 1.67
EV / sales
Details›
- Price / book2025-FY
- 11.9
- EV / EBIT2025-FY
- 8.21
- EV / sales2025-FY
- 1.67
- Market capitalisation
- $104.0B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers - General
Ranks #5 of 7 by Smart Score